News
-
-
-
COMMUNIQUÉ DE PRESSE
Curatis and Neupharma announce exclusive licensing agreement to develop and market corticorelin (C-PTBE-01) for the treatment of peritumoral brain edema in Japan
Curatis Holding AG and Neupharma announce exclusive agreement to develop and market corticorelin (C-PTBE-01) for peritumoral brain edema treatment in Japan. Agreement involves upfront, milestone payments, and royalties -
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
FDA minutes confirm positive outcome of meeting on 9. September 2025 – Corticorelin on track for Phase 3
Curatis Holding AG receives positive outcome confirmation from FDA meeting regarding corticorelin's Phase 3 development plan for patients with PTBE secondary to solid tumor brain metastases -
